Key result
Novel therapies lower Lp(a) by up to ~95%, targeting a causal driver of aortic stenosis.
Why the study?
Calcific aortic stenosis is the most prevalent valvular heart disease in older adults, yet no validated pharmacological intervention can halt its progression. Although elevated lipoprotein(a) is causally implicated in calcific aortic valve lesions, no completed trial has yet demonstrated that lowering lipoprotein(a) modifies the disease.
Does lipoprotein(a)-lowering therapy reduce the initiation and progression of calcific aortic valve stenosis in patients with elevated lipoprotein(a)?
Does lipoprotein(a)-lowering therapy reduce the initiation and progression of calcific aortic valve stenosis in patients with elevated lipoprotein(a)?
This narrative review synthesizes genetic, mechanistic, and clinical evidence establishing elevated Lp(a) as a causal driver of calcific aortic stenosis, while highlighting that ongoing randomized trials (such as Lp(a)FRONTIERS CAVS with pelacarsen) are required to prove whether potent Lp(a)-lowering therapies can slow valve disease progression.
Lp(a) lowering may slow CAVS progression; leaves open whether RNA or oral therapies improve clinical outcomes in ongoing trials.
Calcific aortic stenosis (CAVS) is the most prevalent valvular heart disease affecting older adults, yet no validated pharmacological intervention can halt its progressive deterioration. Lipoprotein(a) [Lp(a)] denotes a genetically regulated low-density lipoprotein (LDL)-like particle, in which apolipoprotein(a) forms a covalent bond with apolipoprotein B-100. Cumulative genetic, epidemiological, imaging and mechanistic research supports a causal role for elevated circulating Lp(a) in the initiation, and suggests a contribution to the advancement, of calcific aortic valve lesions. Lp(a) mediates valve injury mainly via preferentially transporting oxidized phospholipids (OxPL), anchoring within aortic valve leaflets, triggering endothelial activation and inflammatory cascades, as well as stimulating the autotaxin–lysophosphatidic acid (ATX–LPA) axis; collectively these signals drive osteogenic differentiation and mineralization of valve interstitial cells (VICs). Higher Lp(a) levels correlate with incident aortic valve calcification, accelerated hemodynamic deterioration, augmented calcium deposition quantified by computed tomography (CT), and elevated risks of aortic valve replacement (AVR) or all-cause cardiac death. Conventional lipid-lowering agents fail to reverse disease trajectory in patients with established CAVS. Though proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors only modestly cut Lp(a) concentrations, exploratory analyses have delivered preliminary suggestive signals for cardiovascular protection. RNA-targeted therapeutics and oral agents blocking Lp(a) assembly can reduce circulating Lp(a) by 70% up to over 95%, as demonstrated in early- and mid-phase clinical trials. Most notably, the ongoing Lp(a)FRONTIERS CAVS randomized trial is directly testing whether pelacarsen can decelerate CAVS progression, and no completed trial has yet demonstrated that Lp(a) lowering modifies CAVS disease. This narrative review summarizes Lp(a) biological characteristics, causal evidence linking Lp(a) to CAVS, together with opportunities and unresolved uncertainties surrounding Lp(a)-targeted therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a review in Calcific aortic stenosis (CAVS). Lipoprotein(a) [Lp(a)] and Lp(a)-lowering therapies (pelacarsen, olpasiran, lepodisiran, zerlasiran, muvalaplin) was evaluated on Initiation and progression of calcific aortic valve stenosis. Elevated lipoprotein(a) is causally linked to calcific aortic stenosis initiation, and novel RNA and oral therapies reduce circulating Lp(a) by 70% to >95%, with CAVS outcome trials ongoing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: